Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

ABVC BioPharma, Inc. (ABVC) stock profile

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703, which has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702, which has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California, and is a subsidiary of YuanGene Corporation.

Key facts

SymbolABVC
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOUttam Yashwant Patil
Employees18
HeadquartersFremont, CA, US
IPO2004-11-10
Websitewww.abvcpharma.com

Explore ABVC on Vantafin

  • ABVC BioPharma, Inc. Overview
  • ABVC BioPharma, Inc. Financials
  • ABVC BioPharma, Inc. News
  • ABVC BioPharma, Inc. Events
  • ABVC BioPharma, Inc. SEC filings
  • ABVC BioPharma, Inc. Insider transactions

Frequently asked questions

What does ABVC BioPharma, Inc. (ABVC) do?
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703, which has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702, which has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California, and is a subsidiary of YuanGene Corporation.
Where is ABVC stock listed?
ABVC BioPharma, Inc. trades under the ticker ABVC on NASDAQ.
How can I research ABVC's financials and filings?
Vantafin provides ABVC BioPharma, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ABVC profile.